Dr. Weisman Quoted in Philadelphia Inquirer Article about Tofersen

The FDA has recently granted accelerated approval for a new drug, tofersen. This medication, designed to treat a fraction of ALS cases caused by a genetic mutation, has shown promise in maintaining stability in patients’ conditions. Dr. David Weisman, who served on the FDA advisory panel that reviewed the drug, believes in its potential to work over an extended period.

“On March 22, Weisman and his fellow advisers voted unanimously that the drug was ‘reasonably likely’ to prove beneficial, paving the way for the agency to approve it Tuesday.”